Jan A C Hontelez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6856764/publications.pdf

Version: 2024-02-01

47 papers 2,040 citations

304602 22 h-index 265120 42 g-index

48 all docs

48 docs citations

48 times ranked

3013 citing authors

#	Article	IF	CITATIONS
1	HIV Treatment as Prevention: Systematic Comparison of Mathematical Models of the Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa. PLoS Medicine, 2012, 9, e1001245.	3.9	324
2	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health, The, 2016, 1, e8-e17.	4.7	210
3	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	2.9	188
4	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	2.1	187
5	The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. Aids, 2012, 26, S19-S30.	1.0	136
6	Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study. PLoS Medicine, 2013, 10, e1001534.	3.9	124
7	Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness. International Journal of Health Policy and Management, 2016, 5, 615-618.	0.5	80
8	Ageing with HIV in South Africa. Aids, 2011, 25, 1665-1667.	1.0	73
9	Costs, effects and costâ€effectiveness of breast cancer control in Ghana. Tropical Medicine and International Health, 2012, 17, 1031-1043.	1.0	68
10	The Impact of the New WHO Antiretroviral Treatment Guidelines on HIV Epidemic Dynamics and Cost in South Africa. PLoS ONE, 2011, 6, e21919.	1.1	47
11	Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era. The Lancet Global Health, 2015, 3, e598-e608.	2.9	46
12	Concerted Efforts to Control or Eliminate Neglected Tropical Diseases: How Much Health Will Be Gained?. PLoS Neglected Tropical Diseases, 2016, 10, e0004386.	1.3	45
13	Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints. PLoS Medicine, 2017, 14, e1002240.	3.9	42
14	Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study. BMJ Open, 2016, 6, e009656.	0.8	40
15	Looking upstream to prevent HIV transmission. Aids, 2014, 28, 891-899.	1.0	39
16	Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa. Aids, 2016, 30, 2341-2350.	1.0	39
17	The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases. PLoS Neglected Tropical Diseases, 2017, 11, e0005289.	1.3	39
18	Integrating HIV services and other health services: AÂsystematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003836.	3.9	38

#	Article	IF	Citations
19	Mapping and characterising areas with high levels of HIV transmission in sub-Saharan Africa: AÂgeospatial analysis of national survey data. PLoS Medicine, 2020, 17, e1003042.	3.9	34
20	The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model. Vaccine, 2011, 29, 6100-6106.	1.7	30
21	Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. PLoS Neglected Tropical Diseases, 2018. 12. e0006250.	1.3	29
22	Human resources needs for universal access to antiretroviral therapy in South Africa: a time and motion study. Human Resources for Health, 2012, 10, 39.	1.1	23
23	The Role of Acquired Immunity in the Spread of Human Papillomavirus (HPV): Explorations with a Microsimulation Model. PLoS ONE, 2015, 10, e0116618.	1.1	17
24	Epidemiological And Health Systems Implications Of Evolving HIV And Hypertension In South Africa And Kenya. Health Affairs, 2019, 38, 1173-1181.	2.5	17
25	Equity in utilization of antiretroviral therapy for HIV-infected people in South Africa: a systematic review. International Journal for Equity in Health, 2014, 13, 60.	1.5	14
26	Behavioural disinhibition in the general population during the antiretroviral therapy rollâ€out in Subâ€Saharan Africa: systematic review and metaâ€analysis. Tropical Medicine and International Health, 2017, 22, 797-806.	1.0	12
27	The Effect of Antiretroviral Treatment on Health Care Utilization in Rural South Africa: A Population-Based Cohort Study. PLoS ONE, 2016, 11, e0158015.	1.1	11
28	Translating international <scp>HIV</scp> treatment guidelines into local priorities in Indonesia. Tropical Medicine and International Health, 2018, 23, 279-294.	1.0	11
29	Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study. Journal of Infectious Diseases, 2016, 214, 854-861.	1.9	9
30	Economy, migrant labour and sex work. Aids, 2019, 33, 123-131.	1.0	9
31	The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination. Vaccine, 2015, 33, 5357-5364.	1.7	7
32	The costs of HIV treatment and care in Ghana. Aids, 2017, 31, 2279-2286.	1.0	7
33	The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. PLoS ONE, 2018, 13, e0202924.	1.1	7
34	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	1.2	7
35	Impact of the coronavirus disease 2019-related global recession on the financing of the global HIV response. Aids, 2021, 35, 1143-1146.	1.0	7
36	Evidence-based policymaking when evidence is incomplete: The case of HIV programme integration. PLoS Medicine, 2021, 18, e1003835.	3.9	7

#	Article	IF	CITATIONS
37	Effectiveness and impact of hepatitis B virus vaccination of children with at least one parent born in a hepatitis B virus endemic country: an early assessment. Journal of Epidemiology and Community Health, 2010, 64, 890-894.	2.0	6
38	Evidence-Informed Deliberative Processes – Early Dialogue, Broad Focus and Relevance: A Response to Recent Commentaries. International Journal of Health Policy and Management, 2018, 7, 96-97.	0.5	4
39	Which delivery model innovations can support sustainable HIV treatment?. African Journal of AIDS Research, 2019, 18, 315-323.	0.3	3
40	HIV Treatment Substantially Decreases Hospitalization Rates: Evidence From Rural South Africa. Health Affairs, 2018, 37, 997-1004.	2.5	2
41	The Differential Risk of Cervical Cancer in HPV-Vaccinated and -Unvaccinated Women: A Mathematical Modeling Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 912-919.	1.1	1
42	No increased HIV risk in general population near sex work sites: A nationally representative crossâ€sectional study in Zimbabwe. Tropical Medicine and International Health, 2022, 27, 696-704.	1.0	1
43	Title is missing!. , 2020, 17, e1003042.		O
44	Title is missing!. , 2020, 17, e1003042.		0
45	Title is missing!. , 2020, 17, e1003042.		O
46	Title is missing!. , 2020, 17, e1003042.		0
47	Title is missing!. , 2020, 17, e1003042.		O